Microaneurysm

The Industrial Technology Research Institute, a non-profit R&D organisation in Taiwan, has unveiled its AI-assisted system for detecting diabetic eye diseases. WHAT IT'S ABOUT Point-of-care AI-DR can instantly diagnose diabetic retinopathy and diabetic eye oedema in five to 10 seconds. It can locate from fundus images four main lesions – microaneurysms, haemorrhages, soft exudates, and hard exudates – and detect two anatomical landmarks, the optic disc and the macular area. It can further identify 14 other common ocular fundus abnormalities, including retinal-related diseases, changes in blood vessels, and optic nerve-related diseases. AI-DR also provides five severity levels of diabetic retinopathy and produces binary classifications for both diabetic retinopathy and diabetic macular oedema. The AI model has been trained using 150,000 fundus images. In a study, AI-DR was shown to have 98% sensitivity and 96% specificity in diagnosing diabetic retinopathy. According to ITRI, AI-DR can support all available fundus cameras worldwide and be used to create other solutions such as edge AI systems, standalone web applications, and private and public cloud-based services. The organisation has recently provided a use license for AI-DR to Acer for its VeriSee DR diagnostic software. WHY IT MATTERS Last year, there are about 537 million adults between the age of 20 and 79 who have diabetes. The International Diabetes Foundation expects their count to reach 643 million by 2030 and 783 million by 2045. Currently, more than half of people living with diabetes globally will develop DR and about one in 15 will develop DME, according to the US National Eye Institute. ITRI said that with diagnostic solutions like AI-DR, the risks of blindness caused by diabetes complications can be lowered. It also emphasised that in diabetes management today, it is crucial to track changes in fundus symptoms as this can be better monitored than blood sugar levels. Additionally, AI-DR's intuitive design allows GPs and other non-ophthalmologists to perform quick diabetic retinopathy screening as trained ophthalmologists, which can lead to increased screening rates, reduced treatment costs and improved patient outcomes by enabling early detection. MARKET SNAPSHOT Other existing diabetic eye screening software products around Asia-Pacific are also powered by AI, including the ORAiCLE platform by New Zealand-based Toku Eyes, Singapore Eye Lesion Analyzer by the Singapore Eye Research Institute, and VUNO Med-Fundus AI by South Korean medical AI company VUNO. Meanwhile, a recent Google-backed study in Thailand has demonstrated the accurate detection of diabetic retinopathy using a new deep-learning system. Also, Samsung is turning old Galaxy smartphone devices into AI-powered fundus cameras to screen for diabetic eye diseases as part of its upcycling programme to improve access to eye health screening in underserved communities around the world.

Point-of-Care AI-DR is the first AI-assisted system which can be integrated into handheld and desktop fundus cameras used to detect diabetic retinopathy and diabetic macular edema HSINCHU, Nov. 10, 2022 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI), Taiwan's largest and one of the world's leading high-tech applied research institutions, today introduced Point-of-Care AI-DR, the first AI-assisted system which can be integrated into handheld and desktop fundus cameras commonly used in hospitals and clinics to detect diabetic retinopathy (DR) and diabetic macular edema (DME). Point-of-Care AI-DR is a 2022 R&D 100 Awards winner in the software/services award category. Continue Reading Point-of-Care AI-DR is the first AI-based solution that can locate four main lesions, classify five severity levels of DR, and determine whether a patient should be referred to an ophthalmologist. Point-of-Care AI-DR diagnoses DR and DME in 5 to 10 seconds and instantly assesses image quality before diagnosis to prevent misinterpretation by the AI. It marks lesions and assesses the corresponding severity levels based on the fundus images. Further, Point-of-Care AI-DR can identify 14 other common ocular fundus abnormalities, including retinal related diseases, changes in blood vessels, and optic nerve related diseases. Point-of-Care AI-DR is easy to use, so general physicians can perform early screening for DR and DME complications. It also can determine whether a patient should be referred to an ophthalmologist. Screening through general physicians increases screening rates, reduces treatment costs and improves patient outcomes by enabling early detection. According to the International Diabetes Foundation, 537 million adults globally between 20 and 79 years old were living with diabetes in 2021, and the number is projected to increase to 643 million by 2030 and 783 million by 2045. According to the U.S. National Eye Institute, more than half of people with diabetes will develop DR and about one in 15 will develop DME. By identifying lesions and severity stages of DR and DME, Point-of-Care AI-DR improves diabetes health monitoring and management and helps lower the risks of vision loss or blindness caused by diabetic eye complications. Physicians can effectively grasp the patient's diabetes development status by tracking the changes in fundus symptoms over time. This is crucial for diabetes management, because the changes in fundus symptoms can be monitored more reliably than blood sugar levels, which patients can alter immediately before examinations. "Point-of-Care AI-DR is a collaboration of human and artificial intelligence through the expertise of ophthalmologists and AI analysis. It uses complementary medical AI models to perform individual diagnostic tasks such as classifying and detecting symptoms to improve the efficiency of overall interpretation," said Dr. Pang-An Ting, ITRI general director of Information and Communications Research Laboratories. To create Point-of-Care AI-DR, ITRI engaged 50 ophthalmologists who collected and labeled 150,000 fundus images as the training data for robust AI models. As a result, Point-of-Care AI-DR outperforms existing products in terms of sensitivity (>98%) and specificity (>96%) in DR diagnosis and helps non-ophthalmologists perform rapid point-of-care DR screening like ophthalmologists. It can support all existing fundus cameras worldwide and be used to create different types of solutions such as edge AI systems, standalone web applications, and private/public cloud-based services. Point-of-Care AI-DR is the first AI-based solution for DR and DME detection that can: Locate four main lesions: microaneurysms, hemorrhages, soft exudates, and hard exudates, and detect two anatomical landmarks: optic disc and macular area Classify five severity levels of diabetic retinopathy: no DR, mild NPDR, moderate NPDR, severe NPDR and PDR Produce binary classifications of DR and DME so general practitioners can provide data-informed decisions for referrals to ophthalmologists Point-of-Care AI-DR is available for licensing. One example of Point-of-Care AI-DR licensing is VeriSee DR by Acer. Companies interested in licensing should contact ITRI. About ITRI Industrial Technology Research Institute (ITRI) is one of the world's leading technology R&D institutions aiming to innovate a better future for society. Founded in 1973, ITRI has played a vital role in transforming Taiwan's industries from labor-intensive into innovation-driven. To address market needs and global trends, it has launched its 2030 Technology Strategy & Roadmap and focuses on innovation development in Smart Living, Quality Health, and Sustainable Environment. It also strives to strengthen Intelligentization Enabling Technology to support diversified applications. Over the years, ITRI has been dedicated to incubating startups and spinoffs, including well-known names such as UMC and TSMC. In addition to its headquarters in Taiwan, ITRI has branch offices in the U.S., Europe, and Japan in an effort to extend its R&D scope and promote international cooperation across the globe. For more information, please visit . SOURCE Industrial Technology Research Institute